Skip to main content
Evidence Snapshot

Bifunctional epoxide hydrolase 2

CHEMBL2409 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:08:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2409
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional epoxide hydrolase 2 as ChEMBL target CHEMBL2409, mapped to UniProt P34913. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional epoxide hydrolase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2409
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P34913
Bifunctional epoxide hydrolase 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Bifunctional epoxide hydrolase 2 matters

As of 2026-09-14

Bifunctional epoxide hydrolase 2 is reviewed as Bifunctional epoxide hydrolase 2 (UniProt P34913); Bifunctional epoxide hydrolase 2 shows clinical signal disease relevance led by chronic obstructive pulmonary disease.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 3074 compounds, and 274 assays, with lead potency reaching pChEMBL 10.7.

Disease context
chronic obstructive pulmonary disease

Bifunctional epoxide hydrolase 2 shows clinical signal disease relevance led by chronic obstructive pulmonary disease. 1 linked drug keep the rationale reviewable. Linked drugs include GSK2256294.

Start review with chronic obstructive pulmonary disease because it currently carries clinical signal support. Linked drugs include GSK2256294. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 3074 compounds, and 274 assays for this target. The dominant activity type is IC50. CHEMBL3327073 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL3327073 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Bifunctional epoxide hydrolase 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P34913, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why chronic obstructive pulmonary disease is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3074
Total Compounds
274
Total Assays
7
Approved Drugs
IC50: 3396.0, KI: 235.0, EC50: 22.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3327073
 10.7 Ki —
No preferred name
CHEMBL3818875
 10.6 IC50 Clinical
No preferred name
CHEMBL5190894
 10.5 IC50 —
No preferred name
CHEMBL5425833
 10.3 IC50 —
No preferred name
CHEMBL5746598
 10.3 Ki —

Approved Drugs

Structure Compound First Approval
REGORAFENIB
CHEMBL1946170
 2012
SORAFENIB
CHEMBL1336
 2005
FULVESTRANT
CHEMBL1358
 2002
ZILEUTON
CHEMBL93
 1996
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:08:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2409